UNSPSC 51362502: Cloperidone

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8FP5Y6U39R. European Medicines Agency schedules Cloperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06738MIG. Cloperidone generally arises in the molecular formula C21H23CLN4O2.

UNSPSC 51362502 Cloperidone is a Commodity code for pharmaceutical active ingredients and finished pharmaceutical products, though recent state and local opportunities solicited under it focus on naloxone acquisition, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products rather than cloperidone specifically. State and local governments buying under this code range from county health departments pursuing opioid-reversal and harm-reduction supplies to state health and human services commissions structuring pharmacy benefit programs, and multistate cooperative purchasing alliances aggregating pharmaceutical procurement across member jurisdictions. The work spans product procurement with defined NDC codes and specifications, quarterly or ongoing delivery logistics, compliance with cGMP and Drug Supply Chain Security Act requirements, and establishment of contractual relationships with authorized pharmaceutical wholesalers and manufacturers.

Recent opportunities show activity in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and health plans using negotiated net pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and EDI capability; the contract term runs two years with optional extensions for new responders through June 30, 2028.